In spite of ongoing safety concerns for the class as a whole, BMS’s selective JAK inhibitor deucravacitinib has been accepted for review by regulatory agencies
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.